Sign Up
Stories
Otsuka's Phase 3 Trial Results
Share
ABVC BioPharma's Patent and Partnership
Advancements in Psychiatric Treatments
Amneal Resubmits IPX203 for Parkinson’s ...
ANJESO Drug Insight and Market Forecast
AlzeCure's Drug Therapy Focus
Asia Pacific Epilepsy Therapeutic Market...
Overview
API
Otsuka Pharmaceutical's phase 3 trial for AVP-786 to treat agitation associated with dementia due to Alzheimer’s disease did not achieve statistical significance. The company plans to analyze the full data set to determine potential treatment efficacy.
Ask a question
How might Otsuka's focus on pharmaceutical products impact the healthcare industry?
What are the implications of the phase 3 trial results for the treatment of dementia?
What are the potential future directions for Otsuka's research and development efforts?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage